tbuckley/cabot-search huggingface dataset:
PTH-033 Lumen-apposing fully covered self-expanding metal stent versus double pigtail plastic stents for endoscopic ultrasound guided transmural drainage of pancreatic fluid collections
Authors: Y El-Sherif, K Courtney, M Cannon, D Lewis, J Devlin
Journal: Endoscopy (2017)

<h3>Introduction</h3> Endoscopic ultrasound guided transmural drainage (EUD) of pancreatic fluid collections (PFCs) (pancreatic pseudocyst and walled-off necrosis) is an established treatment. EUD has been primarily performed using cystotome and double pigtail plastic stents (DPS). More recently, the novel lumen-apposing fully covered self-expanding metal stents (LAMS) are increasingly preferred over DPS. Its efficacy, however, in terms of technical success rate and clinical outcomes has not yet been fully demonstrated. The aim of this retrospective cohort study is to compare the success rate, clinical outcomes and adverse events (AE) in EUD of PFC with DPS and LAMS. <h3>Method</h3> Consecutive patients with symptomatic PFCs who underwent EUD between 2011 and 2016 were divided into two groups: (i) drainage using DPS, (ii) drainage using LAMS. Clinical outcomes in both groups were evaluated including the technical success rate, early AE (within 7 days), and late AE (within 3 months) of procedure. Cyst resolution was evaluated at 3 months post procedure. <h3>Results</h3> 114 patients (35% female; mean age 51 years) underwent EUD. The aetiology of pancreatitis was gallstones (41%), alcohol (24.5%), idiopathic (24.5%), and miscellaneous causes (10%). Mean cyst size was 110 mm (30–220 mm). 89 patients underwent EUD using DPS, as compared to 25 using LAMS. The two groups were matched for age, sex and cyst size (p&gt;0.05 for all). The overall technical success rate was 75% (86/114). On comparing both groups, successful stent placement was significantly higher in LAMS (92%), than with DPS (71%), p=0.03. Of those with attempted drainage by DPS, the stent could not be deployed in 26 patients (4=failed, 10=aspiration only, 12=track formation only). There was no significant difference between patients in the LAMS or DPS group in relation to intra-procedural complications (12% Vs 13%), early AE (4% Vs 10%) or late AE (16% Vs 8%), all p&gt;0.05. Complete resolution of the PFCs was greater in the LAMS group as compared to the DPS group (92% Vs 80%) with fewer patients undergoing further intervention (8% Vs 20%), but this did not reach statistical significance, p=0.1. <h3>Conclusion</h3> EUS-guided drainage of PFCs using LAMS is superior to DPS in terms of technical success rate. Early experience is suggesting higher resolution rates and less number of procedures required to achieve cyst resolution. <h3>Disclosure of Interest</h3> None Declared
Capecitabine-oxaliplatin (CAPOX) prior to chemoradiotherapy (CRT) and surgery in magnetic resonance imaging (MRI)-defined poor-risk rectal carcinoma (PRRC): A center experience.
Authors: Isabel Busquier, Jorge Soler, Leticia De avila, Maria De Julian, Maria Arnal, Nuria Ruiz, Jorge Molina, Carlos Burriel, Francisco Garcia, Virginia Morillo, Ramon De Las Penas
Journal: Journal of Clinical Oncology (2016)

e15141 Background: Clinical trials have studied the efficacy and safety of neoadjuvant chemotherapy (CT) and CRT in PRRC. Chau published his data on PRRC studied with MRI: tumors within 1 mm of mesorectal fascia, T3 at or below levators, tumors extending > 5 mm into perirectal fat, T4 and T1-4N2 tumors (JCO 2006; 24: 668-674). Following this strategy, we present the data from our center. Methods: Since February 2006-December 2015 we treated 54 patients (PT) with MRI-defined PRRC with CAPOX x 4 cycles, Capecitabine-radiotherapy, surgery and capecitabine 4 cycles (Chau strategy). Results: Our sample includes 27 men and 27 women, median age 58 (range 31-79). A patient died after the first CAPOX due to a hemorrhagic stroke. 51 PT had symptomatic improvement with CT (94%; IC 95%: 88-100), without identifying progression. 52 were resected, 49 had R0 resection, R1 in 2 patients, 1 lost. On an intent-to-treat analysis, pathological complete responses was achieved in 12 (pCR: 22%; IC 95%: 11-33%) of 54 patients. The median lymph nodes examined was 10. Compared with baseline MRI, 42 (80%) of 52 patients had downstaging in T only (n = 4), N only (n = 14), or both T+N (n = 24) staging. In the first month post-surgery a patient died due to sepsis. 38 patients (70%) started CT post-surgery. With a median follow up of 40 months, the 3-years DFS was 71% (IC 95%: 59 –86%), 5 local and 14 distant recurrences. The 3-years OS was 87% (IC 95%: 77-97%). Conclusions: Our data support the rutine use of CAPOX and following CRT prior to surgery on PT with PRRC, with promising results consistent with published trial data.
02.19 Sirt-1 increased human dermal fibroblast migration by stimulated cyr61 expression
Authors: Eun-Jeong Kwon, Eun-Jung Park, Jinseok Kim, Moonjae Cho, Sung Won Lee
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> SIRT1 is a NAD-dependent protein deacetylase that participate in cellular regulation. The increased migration of fibroblast is important phenotype in fibroblast activation. The role of SIRT1 in cell migration remains controversial whether SIRT1 act as an activator or suppressor for cell migration. We have therefore established the role of SIRT1 in human dermal fibroblast migration and explored target of SIRT1 for dermal fibroblast migration. <h3>Results</h3> SIRT1 and Cyr61 were expressed in human dermal fibroblasts and the stimulation of TGF-β further induced expression SIRT1 and Cyr61. Treatment of resveratol (RSV), SIRT1 agonist or overexpression of SIRT1 also promoted expression of SIRT1 and Cyr61 in human dermal fibroblasts, whereas inhibition of SIRT1 activity by nicotinamide or knock down of SIRT1 down-regulated Cyr61 basal level as well as TGF-β or RSV-induced Cyr61expression. Blocking of ERK signalling by PD98509 reduced TGF-β or RSV-induced Cyr61 expression. TGF-β, RSV or SIRT1 vector enhanced β-catenin as well as Cyr61 expression. This stimulation was reduced by Wnt inhibitor, XAV939. RSV increased migration and nicotinamide attenuated RSV-induced migration of human dermal fibroblasts. Furthermore, SIRT1 overexpression promoted cell migration whereas blocking Cyr61 attenuated SIRT1-stimulated migration of human dermal fibroblasts. <h3>Conclusion</h3> SIRT1 increased cell migration by stimulated Cyr61 expression for their target through the ERK and Wnt/β-catenin signalling. SIRT1-induced Cyr61 production is very important for human dermal fibroblasts migration.
Adolescent With Pain and Necrosis Following Intramuscular Injection
Authors: David Greenky, Robert Dixon
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Authors: Marius M. Hoeper, Tilmann Kramer, Zixuan Pan, Christina A. Eichstaedt, Jens Spiesshoefer, Nicola Benjamin, Karen M. Olsson, Katrin Meyer, Carmine Dario Vizza, Anton Vonk-Noordegraaf, Oliver Distler, Christian Opitz, J. Simon R. Gibbs, Marion Delcroix, H. Ardeschir Ghofrani, Doerte Huscher, David Pittrow, Stephan Rosenkranz, Ekkehard Grünig
Journal: European Respiratory Journal (2017)

The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of &lt;5%, 5–10% and &gt;10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p&lt;0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema
Authors: Zonne L.M. Hofman, Steven de Maat, Chiara Suffritti, Andrea Zanichelli, Cassandra van Doorn, Silvie A.E. Sebastian, Nora Veszeli, Dorottya Csuka, Thomas Renné, Gerard Pasterkamp, Marco Cicardi, Henriette Farkas, C. Erik Hack, Coen Maas
Journal: Journal of Allergy and Clinical Immunology (2017)
Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014
Authors: Alice Sanna, Yann Le Strat, Françoise Roudot-Thoraval, Sylvie Deuffic Burban, Patrizia Carrieri, Elisabeth Delarocque-Astagneau, Christine Larsen
Journal: Eurosurveillance (2017)

Given recent profound improvements in the effectiveness of antiviral treatment for chronic Hepatitis C virus (HCV) infection, we aimed to describe the characteristics of patients referred to hepatology expert centres in France from 2000 to 2007 and from 2010 to 2014, and to identify factors associated with severe liver disease at their first visit for evaluation. We analysed data from two sources covering all of France: the former hepatitis C surveillance network, which included patients between 2000 and 2007, and the ANRS CO22 HEPATHER multi-centre cohort, which included patients between 2012 and 2014. Severe liver disease (SLD) was defined as the presence of either cirrhosis (histological, biochemical or clinical) or hepatocellular carcinoma. Multivariable Poisson regression models were used to identify the factors associated with SLD in complete-case analysis and after multiple imputation. Overall, 16,851 patients were included in the analysis and SLD was diagnosed in 11.6%. SLD at first visit was significantly associated with known risk factors (male sex, history of excessive alcohol intake, HCV genotype 3), late referral to hepatologists after diagnosis and HCV diagnosis at an older age. Providing earlier specialised care and treatment may be an important target for public health action.
SPORT SPECIFIC PREVALENCE OF CHONDRAL INJURIES IN THE HIP
Authors: Karen Briggs, Marc Philippon, Christiano Trinidade, Maglione Daniela
Journal: British Journal of Sports Medicine (2017)

<h3>Background</h3> Cartilage defect in the hip can progress to osteoarthritis. It is unclear if certain sports put an individual at increased risk of cartilage injury. <h3>Objective</h3> The purpose of this study was to determine the prevalence of chondral defects in the an active population of recreational and elite athletes that underwent hip arthroscopy for femoroacetabular impingment (FAI). <h3>Design</h3> Comparative cohort. <h3>Setting</h3> Clinical recreational to elite athletes. <h3>Patients (or Participants)</h3> 1037 (769 recreational/amateur and 268 professional athletes)patients between 18 to 50 years old. The exclusion criteria included joint space of 2 mm or less, patients over the age of 50 and nonactive individuals. <h3>Interventions (or Assessment of Risk Factors)</h3> Independent variable was presence of cartilage damage in the hip. <h3>Main Outcome Measurements</h3> Type of Sports: Rotational sports; Repetitive non weightbearing; Running sports; Snow sports; Soccer; Football; Hockey; Dance. <h3>Results</h3> Chondral defects were seen in 822 of 1037 hips. In professional athletes, 86% had a chondral defect and in recreational 77% had a chondral defect (p=0.002). Grade III/IV defects were seen in 476 of 1037 hips. In professional athletes, 50% had grade III/IV defects and 45% in recreational athletes (p=0.155).The prevalence of chondral defects was different by sport for both amateur (p=&lt;0.001) and professional athletes (p=0.001). Grade 3 or 4 defects in professionals were most commonly see in soccer, football and hockey. Grade 3 or 4 defects in recreational/amateur athletes were most commonly seen in football, hockey and skiing. Significant differences between pro and recreational athletes was seen in hockey, rotational sports and running. <h3>Conclusions</h3> Prevalence was different between sports and level of athletes. Sports involving contact, such as football, soccer, hockey, had higher risk of more severe defects (grade III / IV), as was snow sports with falls at high speed and sports involving repetitive rotation movements leading to high forces crossing the joint.
PTU-086 Does an effective hospital alcohol liason service have an impact on hcc surveillance
Authors: V Patel, A-T Butt, C Dillon, C Pritchard, H Sennitt, H Carey, A Lo, P Aung, A Hancock
Journal: Gut (2017)

Introduction  Hepatocellular Carcinoma (HCC) is the 17th most common cancer in the UK (new diagnoses, 2014) 1 . Between 2002–2004 and 2011–2013 average incidence of primary liver cancer increased significantly: 55% among males; 46% among females 2 . Early detection and intervention improves patient outcomes.  In April 2013 Tameside General Hospital introduced a Hospital Alcohol Liaison Service (HALS) which screens all patients admitted with alcohol related harms. HALS educates patients, advises on their inpatient management, runs the ambulatory clinic, and facilitates discharge to community services promptly and appropriately. Their goal was to reduce liver harm and related mortality. We believe this increases compliance with HCC surveillance programmes.  Method  We have conducted a retrospective audit of all cases coded as “Cirrhosis” (ICD-10: K70.3, K74.6) between 2012 to 2016 at a DGH in Greater Manchester. Each EPR was accessed to ascertain timing of alpha-fetoprotein (AFP) testing, timing of imaging of the liver, and documented diagnosis. Current BSG guidelines suggest 6 monthly AFP and ultrasound scan (USS) to surveil formation of HCC in high risk population groups.  For the purposes of our audit, we have attempted to identify whether patients were receiving AFP and liver imaging in a 12 monthly period. Search criteria were broadened to include MRI and CT images of the liver as these would be non-inferior to USS in terms of assessing cirrhosis and presence of focal lesions.  Results  An increasing number of patients were given diagnoses of cirrhosis per year:  These numbers of patients required surveillance:  These numbers of patients received surveillance:  Conclusion  We conclude introduction of a HALS service improves compliance with surveillance in cirrhotic patients. This will increase early detection of HCC, increase treatment options, and decrease mortality.  References  . Cancer Research UK, http://www.cancerresearchuk.org/sites/default/files/cstream-node/inc_20common_persons_I14_0.pdf, [Accessed Feb. 2017]  . Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Three [Accessed Feb. 2017]  Disclosure of Interest  None Declared
A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.
Authors: Jayesh Desai, Ben Markman, Shahneen Kaur Sandhu, Hui Kong Gan, Michael Friedlander, Ben Tran, Tarek Meniawy, Vishal Boolell, Duncan Colyer, Christie Norris, Malaka Ameratunga, Jason Yang, Kang Li, Lai Wang, Lusong Luo, Zhen Qin, Michael Millward
Journal: Journal of Clinical Oncology (2016)

3066 Background: BGB-A317 is a humanized IgG4 anti-PD-1 mAb with high specificity and affinity (KD = 0.15 nM) for PD-1. It blocks PD-L1 and PD-L2 binding, and inhibits PD-1-mediated negative signaling in T-cell lines and tumor growth in a number of allogeneic xenograft models. Methods: A phase I, multicenter study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of BGB-A317 in patients (pts) with advanced solid tumors. A 3+3 dose escalation design was undertaken. Pts received escalating doses of BGB-A317 intravenously biweekly (Q2W). Additional pts were treated at 2 and 5 mg/kg either Q2W or Q3W to explore alternate schedules. Results: As of 15 Dec, 2015, 61 patients were treated across 4 dose-escalating cohorts of BGB-A317 Q2W (0.5 mg/kg, n = 3; 2 mg/kg, n = 6; 5 mg/kg, n = 6 and 10 mg/kg, n = 6) and 4 dose-expansion cohorts (2 mg/kg, Q2W, n = 20; 2 mg/kg, Q3W, n = 2; 5 mg/kg Q2W, n = 17 and 5 mg/kg, Q3W, n = 1). One DLT (1/6) of grade 3 colitis was observed in the 5 mg/kg Q2W cohort. Maximum tolerated dose was not reached. The most common treatment-emergent adverse events (AEs) were grade (G) 1-2 fatigue (25%), diarrhea (20%), nausea (16%), rash (13%), pruritus (11%) and abdominal pain (11%). Treatment–related G3 AEs included diabetic ketoacidosis (n = 1, 2 mg/kg Q2W), hypotension (n = 1, 2 mg/kg Q2W), colitis (n = 2, 5 mg/kg Q2W), elevated ALT (n = 1, 2 mg/kg Q2W), hyperglycaemia (n = 1, 2 mg/kg Q2W) and fatigue (n = 1, 5 mg/kg Q2W). PKs of BGB-A317 show dose-proportional exposure increase from 0.5 to 10 mg/kg Q2W after the single dose administration with the elimination half-life of 11 to 17 days. Among 39 evaluable pts to date (10 ovarian, 6 colorectal, 6 RCC, 4 cutaneous SCC, 3 mesothelioma, 2 cervical, and 1 each of 8 others), 3 pts have partial response (2 to be confirmed) (1 gastric, 1 RCC and 1 cervical) and a further 13 pts exhibit stable disease. All 3 responding pts remain on treatment, ranging from 13 to 23 weeks. Conclusions: BGB-A317 demonstrates a favorable safety profile with AEs in keeping with the class effect. PKs are linear and early promising anti-tumor activity has been observed. The expansion cohorts are ongoing and an expanded phase IB study in selected cancer types is planned. Clinical trial information: NCT02407990.
MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC
Authors: Leora Horn, Heather Wakelee, Karen L. Reckamp, George Blumenschein, Jeffrey R. Infante, Corey A. Carter, Saiama N. Waqar, Joel W. Neal, Kimberly Harrow, Jon P. Gockerman, Gary Dukart, Chris Liang, James L. Gibbons, Jennifer Hernandez, Tera Newman-Eerkes, Lee Lim, Christine M. Lovly
Journal: Journal of Thoracic Oncology (2016)
02.29 Exploring pim1 as a measurable therapeutic target in early rheumatoid arthritis
Authors: Nicola J Maney, Amy E Anderson, Amine Turay, John D Isaacs, Arthur G Pratt
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Biomarkers that stratify rheumatoid arthritis (RA) patients according to responsiveness to existing and emerging therapeutics are urgently required. We previously showed the protein kinase PIM1 to be strikingly up-regulated in CD4<sup>+</sup> T cells of untreated early RA (eRA) patients compared with disease controls at the RNA level.<sup>1</sup> PIM1 has a recognised role in T cell development and is implicated in the pathogenesis of inflammatory diseases including RA. We hypothesised that, amongst an identifiable subgroup of eRA patients, measurable PIM1 overexpression in CD4<sup>+</sup> T cells is a targetable early event in pathogenesis. <h3>Methods</h3> Peripheral blood (PB) was obtained from consenting, treatment-naïve eRA patients. Western blotting and immunofluorescence were used to determine relative expression and sub-cellular localization of PIM1 in PB CD4<sup>+</sup> T cells isolated by positive selection, in order to validate our observations at a protein level. A PIM1-specific small molecule inhibitor (TCS PIM-1 1, Tocris) and flow cytometric analysis were used to assess its potential role in the activation and proliferation of CD4<sup>+</sup> T cells following CD3/CD28-mediated stimulation. <h3>Results</h3> Disease-specific PIM1 up-regulation at a protein level was confirmed, with detectable levels seen in the CD4<sup>+</sup> T cells of eRA patients in contrast to healthy controls. We observed that circulating CD4<sup>+</sup> T cells of eRA patients have an activated, hyper-proliferative phenotype (significantly higher CD25 and ki67 expression) compared to healthy controls. The use of a PIM1-specific small molecule inhibitor appeared to decrease both the activation (CD25 expression) and proliferation (CFSE dilution) of stimulated <i>ex vivo</i> CD4+ T cells. Preliminary data suggest that this effect may be more pronounced in cells derived from eRA patients compared with controls. <h3>Conclusions</h3> Taken together, these data implicate PIM1 as prominent amongst genes whose induction 'pre-programmes' CD4<sup>+</sup> T cells to function aberrantly in disease. The resultant activated and hyper-proliferative phenotype is reminiscent of that we have observed in eRA, and appears to reflect known roles of PIM1 in T cell biology. Future work will include PIM1 knock down in primary CD4<sup>+</sup> T cells to further determine its biological role. <h3>Reference</h3> Pratt AG<i>et al</i>, <i>Ann Rheum Dis</i>71(8):1374–81.
TFR細胞による抑制は,B細胞のエフェクター機能の持続的,選択的阻害に導く
Authors: Sage Peter T, Ron‐Harel Noga, Juneja Vikram R, Sen Debattama R, Maleri Seth, Sungnak Waradon, Kuchroo Vijay K, Haining W Nicholas, Chevrier Nicolas, Haigis Marcia, Sharpe Arlene H
Journal: Nature Immunology (2016)
The Potential of Liquid Marbles for Biomedical Applications: A Critical Review
Authors: Nuno M. Oliveira, Rui L. Reis, João F. Mano
Journal: Advanced Healthcare Materials (2017)

Abstract Liquid marbles (LM) are freestanding droplets covered by micro/nanoparticles with hydrophobic/hydrophilic properties, which can be manipulated as a soft solid. The phenomenon that generates these soft structures is regarded as a different method to generate a superhydrophobic behavior in the liquid/solid interface without modifying the surface. Several applications for the LM have been reported in very different fields, however the developments for biomedical applications are very recent. At first, the LM properties are reviewed, namely shell structure, LM shape, evaporation, floatability and robustness. The different strategies for LM manipulation are also described, which make use of magnetic, electrostatic and gravitational forces, ultraviolet and infrared radiation, and approaches that induce LM self‐propulsion. Then, very distinctive applications for LM in the biomedical field are presented, namely for diagnostic assays, cell culture, drug screening and cryopreservation of mammalian cells. Finally, a critical outlook about the unexplored potential of LM for biomedical applications is presented, suggesting possible advances on this emergent scientific area.